RecruitingNCT02855476

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

Sponsor

University College, London

Enrollment

2,500 participants

Start Date

Jan 1, 2017

Study Type

OBSERVATIONAL

Conditions

Huntington’s Disease

Summary

HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. The secondary objective is to generate a high quality plasma sample collection matching the CSF collections, which will also be used to evaluate biomarkers and pathways of relevance to HD research and development.

Eligibility

Min Age: 11 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with huntington’s disease. The study is currently recruiting participants at 40 locations. People eligible for this study include aged 11 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(40)

Cenexel

Englewood, Colorado, United States

Georgetown University

Washington D.C., District of Columbia, United States

John Hopkins University

Baltimore, Maryland, United States

Wake Forest University

Winston-Salem, North Carolina, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

University of Texas Health Science Center

Houston, Texas, United States

University of British Columbia, The Centre for Huntingtons Disease

Vancouver, British Columbia, Canada

The Ottawa Hospital

Ottawa, Ontario, Canada

North York General Hospital

Toronto, Ontario, Canada

Centre for Movement Disorders

Toronto, Ontario, Canada

Centre Hospitalier Universitaire d'Angers

Angers, France

Le Centre Hospitalier Universitaire de Bordeaux

Bordeaux, France

University Hospital Ulm

Ulm, Baden-Wurttemberg, Germany

Dresden University

Dresden, Saxony, Germany

St Josef And Elisabeth Hospital

Bochum, Germany

University Hospital of Erlangen

Erlangen, Germany

George Huntington Institute

Münster, Germany

Kbo-Isar-Amper-Klinikum Taufkirchen (Vils)

Taufkirchen, Germany

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Milan, Italy

Lega Italiana Ricera Huntington

Rome, Italy

The University of Auckland

Grafton, Auckland, New Zealand

NZ Brain Research Institute

Christchurch, Canterbury, New Zealand

Institute of Psychiatry and Neurology

Warsaw, Poland

Gulbenkian Institute of Molecular Medicine

Lisbon, Portugal

Cruces University Hospital

Bilbao, Biscay, Spain

Hospital de Sant Pau

Barcelona, Spain

Ramón y Cajal Universitary Hospital

Madrid, Spain

Royal Devon & Exeter NHS Foundation Trust

Exeter, Devon, United Kingdom

Glasgow Clinical Research Facility

Glasgow, Scotland, United Kingdom

Birmingham Huntingtons Disease Clinic

Birmingham, West Midlands, United Kingdom

North Bristol NHS Trust

Bristol, United Kingdom

Cambridge University Hospitals NHS Foundation Trust

Cambridge, United Kingdom

Cardiff University

Cardiff, United Kingdom

Fife Health Board - Whyteman's Brae Hospital

Kirkcaldy, United Kingdom

Leeds Teaching Hospital Trust

Leeds, United Kingdom

The Walton Centre NHS Foundation Trust

Liverpool, United Kingdom

University College London Hospitals NHS Foundation Trust

London, United Kingdom

St George's University Of London

London, United Kingdom

Oxford University Hospitals NHS Foundation Trust

Oxford, United Kingdom

University Hospitals Plymouth NHS Trust

Plymouth, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02855476

Related Trials

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

NCT0658544919 locations

A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

NCT075360612 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

NCT072469414 locations

iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009

NCT066346281 location

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

NCT01574053183 locations